Multiple Myeloma Insights

Exclusive Financial Guide, New Clinical Study, and Transformative Treatment Insights

Author

Liam Ball
January 23, 2025

Exclusive Report

Unlocking support: a guide to financial and insurance resources for multiple myeloma patients

Earlier this week, we shared an exclusive guide created in collaboration with AllMyHealth to help you manage the financial challenges of living with multiple myeloma. If you missed it, don't worry! We're highlighting it again in our weekly newsletter to ensure you have access to these valuable resources.

This report simplifies the complex world of financial and insurance support, providing actionable guidance to help you navigate the costs associated with multiple myeloma.

Equip yourself with the tools to confidently manage treatment expenses. Don't miss out — read the full report and share it with others who might benefit!

View the Full Report

The report is available for free online on the AllMyHealth website.

www.allmyhealth.io/report

Top Stories

New Factors Identified to Predict Treatment Outcomes in Myeloma Patients

Researchers are identifying potential prognostic factors that could help predict treatment outcomes and risks for patients with multiple myeloma. These factors may include genetic mutations, immune system responses, and other biomarkers that can guide personalized treatment plans.

Read More →

New Treatment Boosts Survival in Myeloma, But Experts Express Caution

A new study shows that adding belantamab mafodotin to a standard treatment for multiple myeloma can improve survival rates, but experts are cautious due to the drug's side effects. The treatment combination is being closely monitored for its long-term benefits and risks.

Read More →

Belantamab Mafodotin's Role in Treating Relapsed Myeloma Patients

Dr. Rifkin discusses the potential of belantamab mafodotin, a targeted therapy, in treating relapsed or refractory multiple myeloma, highlighting its efficacy and unique mechanism of action. This treatment offers hope for patients who have exhausted other treatment options.

Read More →

EU Approves Isatuximab Plus VRD for Newly Diagnosed Myeloma Patients

Isatuximab, combined with lenalidomide, bortezomib, and dexamethasone (VRd), has been approved in the EU for treating newly diagnosed, transplant-ineligible patients with multiple myeloma. This combination therapy offers a new treatment option for these patients, potentially improving outcomes.

Read More →

Latest Research

A recent case report by Patel et al. (2025) highlights the diagnostic challenges of multiple myeloma in younger patients, particularly when presenting with atypical symptoms. The report emphasizes the importance of considering multiple myeloma in differential diagnoses, even in the absence of common signs, to avoid delays in treatment.

In the realm of treatment, a study registered on ClinicalTrials.gov (2025) is exploring a new drug combination for high-risk smouldering myeloma, aiming to prevent or delay progression to active multiple myeloma. This could potentially offer a proactive treatment approach for patients with this early form of the disease.

Meanwhile, research by Yu et al. (2025) sheds light on the mechanisms of drug resistance in multiple myeloma. Their findings suggest that overexpression of the PSMA4 gene leads to metabolic changes that contribute to resistance against bortezomib, a common therapeutic agent. This discovery could pave the way for new strategies to overcome chemoresistance in multiple myeloma treatment.